Estimated Aggregate Treatment Benefit With Addition of Multiple Novel Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease

• Հիմնական հեղինակներ: Robert W. Ariss BS (Հեղինակ), Rajesh Gupta MD (Հեղինակ)
• Ձևաչափ: Գիրք
• Հրապարակվել է: SAGE Publishing, 2022-03-01T00:00:00Z.
• Խորագրեր: article
• Առցանց հասանելիություն: Connect to this object online.

Purpose: Interest in improving residual cardiovascular (CV) risk by targeting multiple causative pathways has been growing. Several medications including icosapent ethyl, rivaroxaban, and ezetimibe have been shown to individually improve outcomes in the secondary prevention of atherosclerotic cardio...